Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Isosorbide + betahistine** is a combination of two small molecule drugs: isosorbide, an osmotic diuretic, and betahistine, a histamine-like antivertigo agent. Isosorbide acts as an osmotic diuretic to reduce inner ear fluid overload, leveraging its ability to decrease endolymphatic pressure in the inner ear, and is sometimes used in the management of Ménière's disease[3][4][5]. Betahistine functions primarily as a histamine H1-receptor agonist and H3-receptor antagonist; it increases cochlear blood flow and reduces endolymphatic pressure as well, providing symptomatic relief of vertigo in Ménière's disease[1][4][5]. This combination seeks to target both the fluid overload and the vestibular symptoms in the disease, though evidence for the benefit of combination therapy is limited and based on small clinical studies[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isosorbide + betahistine.